Is CAPR or CBUS more profitable?

Capricor Therapeutics has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Capricor Therapeutics' return on equity of -56.60% beat Cibus' return on equity. Company Net Margins Return on Equity Return on Assets Capricor Therapeutics N/A -56.60% -43.97% Cibus -2,258.89% -287.03% -27.99%

Does the media favor CAPR or CBUS?

In the previous week, Capricor Therapeutics had 7 more articles in the media than Cibus. MarketBeat recorded 12 mentions for Capricor Therapeutics and 5 mentions for Cibus. Cibus' average media sentiment score of 0.18 beat Capricor Therapeutics' score of 0.10 indicating that Cibus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cibus 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MNPR or CBUS more profitable?

Monopar Therapeutics has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Monopar Therapeutics' return on equity of -13.08% beat Cibus' return on equity. Company Net Margins Return on Equity Return on Assets Monopar Therapeutics N/A -13.08% -12.79% Cibus -2,258.89% -287.03% -27.99%

Does the media prefer MNPR or CBUS?

In the previous week, Monopar Therapeutics had 2 more articles in the media than Cibus. MarketBeat recorded 7 mentions for Monopar Therapeutics and 5 mentions for Cibus. Monopar Therapeutics' average media sentiment score of 0.42 beat Cibus' score of 0.18 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cibus 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, PROK or CBUS?

ProKidney has higher earnings, but lower revenue than Cibus. ProKidney is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ProKidney $890K 584.26 -$68.99M -$0.55 N/A Cibus $3.64M 35.91 -$127.08M -$1.65 N/A

Is PROK or CBUS more profitable?

Cibus has a net margin of -2,258.89% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Cibus' return on equity. Company Net Margins Return on Equity Return on Assets ProKidney -10,288.39% N/A -27.39% Cibus -2,258.89% -287.03% -27.99%

Does the media prefer PROK or CBUS?

In the previous week, Cibus had 2 more articles in the media than ProKidney. MarketBeat recorded 5 mentions for Cibus and 3 mentions for ProKidney. ProKidney's average media sentiment score of 0.18 beat Cibus' score of 0.18 indicating that ProKidney is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProKidney 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cibus 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, NGNE or CBUS?

Neurogene has higher earnings, but lower revenue than Cibus. Neurogene is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neurogene $930K 551.89 -$90.35M -$5.03 N/A Cibus $3.64M 35.91 -$127.08M -$1.65 N/A

Is NGNE or CBUS more profitable?

Neurogene has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Neurogene's return on equity of -45.10% beat Cibus' return on equity. Company Net Margins Return on Equity Return on Assets Neurogene N/A -45.10% -41.00% Cibus -2,258.89% -287.03% -27.99%

Does the media prefer NGNE or CBUS?

In the previous week, Cibus had 2 more articles in the media than Neurogene. MarketBeat recorded 5 mentions for Cibus and 3 mentions for Neurogene. Neurogene's average media sentiment score of 0.50 beat Cibus' score of 0.18 indicating that Neurogene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cibus 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, ENTX or CBUS?

Entera Bio has higher earnings, but lower revenue than Cibus. Entera Bio is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Entera Bio $40K 12,435.28 -$11.44M -$0.35 N/A Cibus $3.64M 35.91 -$127.08M -$1.65 N/A

Is ENTX or CBUS more profitable?

Entera Bio has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Entera Bio's return on equity of -147.19% beat Cibus' return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -147.19% -103.22% Cibus -2,258.89% -287.03% -27.99%

Does the media prefer ENTX or CBUS?

In the previous week, Cibus had 1 more articles in the media than Entera Bio. MarketBeat recorded 5 mentions for Cibus and 4 mentions for Entera Bio. Cibus' average media sentiment score of 0.18 beat Entera Bio's score of 0.15 indicating that Cibus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entera Bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cibus 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cibus (CBUS) Competitors

$1.71 +0.08 (+4.91%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.71 0.00 (0.00%)

As of 10/2/2026 07:30 PM Eastern

Compare

CBUS vs. CAPR, MNPR, PROK, NGNE, and ENTX

Should you buy Cibus stock or one of its competitors? Cibus's main competitors and comparable companies include Capricor Therapeutics (CAPR), Monopar Therapeutics (MNPR), ProKidney (PROK), Neurogene (NGNE), and Entera Bio (ENTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cibus compare to Capricor Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and Cibus (NASDAQ:CBUS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Capricor Therapeutics presently has a consensus price target of $30.25, suggesting a potential upside of 237.99%. Cibus has a consensus price target of $9.00, suggesting a potential upside of 426.32%. Given Cibus' higher possible upside, analysts plainly believe Cibus is more favorable than Capricor Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Capricor Therapeutics has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Capricor Therapeutics' return on equity of -56.60% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-56.60%	-43.97%
Cibus	-2,258.89%	-287.03%	-27.99%

In the previous week, Capricor Therapeutics had 7 more articles in the media than Cibus. MarketBeat recorded 12 mentions for Capricor Therapeutics and 5 mentions for Cibus. Cibus' average media sentiment score of 0.18 beat Capricor Therapeutics' score of 0.10 indicating that Cibus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cibus	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 33.8% of Cibus shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by insiders. Comparatively, 29.9% of Cibus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Capricor Therapeutics has higher revenue and earnings than Cibus. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	23.37	-$105.04M	-$2.45	N/A
Cibus	$3.64M	35.91	-$127.08M	-$1.65	N/A

Capricor Therapeutics has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Cibus has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market.

Summary

Cibus beats Capricor Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Cibus compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Cibus (NASDAQ:CBUS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Monopar Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Cibus has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

Monopar Therapeutics has higher earnings, but lower revenue than Cibus. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A
Cibus	$3.64M	35.91	-$127.08M	-$1.65	N/A

In the previous week, Monopar Therapeutics had 2 more articles in the media than Cibus. MarketBeat recorded 7 mentions for Monopar Therapeutics and 5 mentions for Cibus. Monopar Therapeutics' average media sentiment score of 0.42 beat Cibus' score of 0.18 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cibus	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Monopar Therapeutics has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Monopar Therapeutics' return on equity of -13.08% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-13.08%	-12.79%
Cibus	-2,258.89%	-287.03%	-27.99%

Monopar Therapeutics currently has a consensus target price of $122.00, suggesting a potential upside of 56.47%. Cibus has a consensus target price of $9.00, suggesting a potential upside of 426.32%. Given Cibus' higher possible upside, analysts plainly believe Cibus is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 33.8% of Cibus shares are owned by institutional investors. 9.7% of Monopar Therapeutics shares are owned by company insiders. Comparatively, 29.9% of Cibus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Monopar Therapeutics beats Cibus on 9 of the 16 factors compared between the two stocks.

How does Cibus compare to ProKidney?

ProKidney (NASDAQ:PROK) and Cibus (NASDAQ:CBUS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

In the previous week, Cibus had 2 more articles in the media than ProKidney. MarketBeat recorded 5 mentions for Cibus and 3 mentions for ProKidney. ProKidney's average media sentiment score of 0.18 beat Cibus' score of 0.18 indicating that ProKidney is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProKidney	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cibus	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cibus has a net margin of -2,258.89% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-10,288.39%	N/A	-27.39%
Cibus	-2,258.89%	-287.03%	-27.99%

ProKidney has higher earnings, but lower revenue than Cibus. ProKidney is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	584.26	-$68.99M	-$0.55	N/A
Cibus	$3.64M	35.91	-$127.08M	-$1.65	N/A

ProKidney presently has a consensus target price of $12.00, suggesting a potential upside of 597.67%. Cibus has a consensus target price of $9.00, suggesting a potential upside of 426.32%. Given ProKidney's stronger consensus rating and higher possible upside, equities research analysts clearly believe ProKidney is more favorable than Cibus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

51.6% of ProKidney shares are owned by institutional investors. Comparatively, 33.8% of Cibus shares are owned by institutional investors. 39.8% of ProKidney shares are owned by insiders. Comparatively, 29.9% of Cibus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ProKidney has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, Cibus has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

Summary

ProKidney beats Cibus on 12 of the 16 factors compared between the two stocks.

How does Cibus compare to Neurogene?

Neurogene (NASDAQ:NGNE) and Cibus (NASDAQ:CBUS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Neurogene currently has a consensus price target of $83.67, suggesting a potential upside of 226.19%. Cibus has a consensus price target of $9.00, suggesting a potential upside of 426.32%. Given Cibus' higher probable upside, analysts clearly believe Cibus is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Cibus had 2 more articles in the media than Neurogene. MarketBeat recorded 5 mentions for Cibus and 3 mentions for Neurogene. Neurogene's average media sentiment score of 0.50 beat Cibus' score of 0.18 indicating that Neurogene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cibus	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neurogene has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Neurogene's return on equity of -45.10% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-45.10%	-41.00%
Cibus	-2,258.89%	-287.03%	-27.99%

Neurogene has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market. Comparatively, Cibus has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

52.4% of Neurogene shares are owned by institutional investors. Comparatively, 33.8% of Cibus shares are owned by institutional investors. 11.7% of Neurogene shares are owned by company insiders. Comparatively, 29.9% of Cibus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Neurogene has higher earnings, but lower revenue than Cibus. Neurogene is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	551.89	-$90.35M	-$5.03	N/A
Cibus	$3.64M	35.91	-$127.08M	-$1.65	N/A

Summary

Neurogene beats Cibus on 10 of the 17 factors compared between the two stocks.

How does Cibus compare to Entera Bio?

Entera Bio (NASDAQ:ENTX) and Cibus (NASDAQ:CBUS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Entera Bio has higher earnings, but lower revenue than Cibus. Entera Bio is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$40K	12,435.28	-$11.44M	-$0.35	N/A
Cibus	$3.64M	35.91	-$127.08M	-$1.65	N/A

14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 33.8% of Cibus shares are owned by institutional investors. 10.6% of Entera Bio shares are owned by insiders. Comparatively, 29.9% of Cibus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Cibus had 1 more articles in the media than Entera Bio. MarketBeat recorded 5 mentions for Cibus and 4 mentions for Entera Bio. Cibus' average media sentiment score of 0.18 beat Entera Bio's score of 0.15 indicating that Cibus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entera Bio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cibus	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Entera Bio currently has a consensus price target of $9.60, suggesting a potential upside of 235.66%. Cibus has a consensus price target of $9.00, suggesting a potential upside of 426.32%. Given Cibus' higher possible upside, analysts clearly believe Cibus is more favorable than Entera Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Entera Bio has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Cibus has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market.

Entera Bio has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Entera Bio's return on equity of -147.19% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-147.19%	-103.22%
Cibus	-2,258.89%	-287.03%	-27.99%

Summary

Cibus beats Entera Bio on 9 of the 17 factors compared between the two stocks.

Get Cibus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CBUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CBUS vs. The Competition

Export

Metric	Cibus	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$130.69M	$3.85B	$7.15B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.33%
P/E Ratio	-1.04	13.00	274.71	26.04
Price / Sales	35.91	1,288.64	656.46	105.13
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	4.28	16.57	10.93	6.31
Net Income	-$127.08M	-$22.66M	$3.51B	$362.16M
7 Day Performance	12.50%	-2.97%	-2.00%	-1.66%
1 Month Performance	7.55%	-10.82%	-6.19%	-4.68%
1 Year Performance	18.75%	19.00%	8.03%	1.57%

Cibus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CBUS Cibus	1.8878 of 5 stars	$1.71 +4.9%	$9.00 +426.3%	+18.8%	$130.69M	$3.64M	N/A	118	News Coverage Analyst Upgrade High Trading Volume
CAPR Capricor Therapeutics	3.1666 of 5 stars	$8.98 +0.4%	$30.25 +237.0%	+21.6%	$521.23M	$22.27M	N/A	231
MNPR Monopar Therapeutics	2.933 of 5 stars	$77.54 -0.6%	$122.00 +57.3%	-21.6%	$520.39M	N/A	N/A	22	News Coverage
PROK ProKidney	1.6662 of 5 stars	$1.72 +0.3%	$12.00 +599.7%	-37.2%	$518.48M	$890K	N/A	231	News Coverage
NGNE Neurogene	2.7449 of 5 stars	$24.97 -5.9%	$83.67 +235.0%	+14.8%	$499.65M	$930K	N/A	131	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CBUS) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cibus (CBUS) Competitors

CBUS vs. CAPR, MNPR, PROK, NGNE, and ENTX

How does Cibus compare to Capricor Therapeutics?

Summary

How does Cibus compare to Monopar Therapeutics?

Summary

How does Cibus compare to ProKidney?

Summary

How does Cibus compare to Neurogene?

Summary

How does Cibus compare to Entera Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBUS vs. The Competition

Cibus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cibus (CBUS) Competitors

CBUS vs. CAPR, MNPR, PROK, NGNE, and ENTX

How does Cibus compare to Capricor Therapeutics?

Do analysts recommend CAPR or CBUS?

Is CAPR or CBUS more profitable?

Does the media favor CAPR or CBUS?

Do institutionals and insiders have more ownership in CAPR or CBUS?

Which has stronger valuation & earnings, CAPR or CBUS?

Which has more risk and volatility, CAPR or CBUS?

Summary

How does Cibus compare to Monopar Therapeutics?

Which has more risk & volatility, MNPR or CBUS?

Which has stronger earnings & valuation, MNPR or CBUS?

Does the media prefer MNPR or CBUS?

Is MNPR or CBUS more profitable?

Do analysts recommend MNPR or CBUS?

Do insiders & institutionals hold more shares of MNPR or CBUS?

Summary

How does Cibus compare to ProKidney?

Does the media prefer PROK or CBUS?

Is PROK or CBUS more profitable?

Which has stronger valuation and earnings, PROK or CBUS?

Do analysts rate PROK or CBUS?

Do insiders and institutionals hold more shares of PROK or CBUS?

Which has more risk & volatility, PROK or CBUS?

Summary

How does Cibus compare to Neurogene?

Do analysts rate NGNE or CBUS?

Does the media prefer NGNE or CBUS?

Is NGNE or CBUS more profitable?

Which has more volatility & risk, NGNE or CBUS?

Do institutionals & insiders hold more shares of NGNE or CBUS?

Which has better earnings & valuation, NGNE or CBUS?

Summary

How does Cibus compare to Entera Bio?

Which has preferable valuation and earnings, ENTX or CBUS?

Do insiders and institutionals hold more shares of ENTX or CBUS?

Does the media prefer ENTX or CBUS?

Do analysts rate ENTX or CBUS?

Which has more risk & volatility, ENTX or CBUS?

Is ENTX or CBUS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBUS vs. The Competition

Cibus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools